Literature DB >> 20153809

Amyloid load in nondemented brains correlates with APOE e4.

Richard J Caselli1, Douglas Walker, Lucia Sue, Marwan Sabbagh, Thomas Beach.   

Abstract

179 Cognitively healthy adults enrolled in the Sun Health Brain Donation program between 7/91 and 12/07 were at least 60 years old and nondemented at the time of death (21 had developed mild cognitive impairment [MCI]). Amyloid plaque density, congophilic amyloid angiopathy (CAA), and neurofibrillary tangle (NFT) density scores were based on CERAD criteria and compared in apolipoprotein E (APOE) e4 carriers (n=42) and noncarriers (NC) (n=137). Mean age (83.4+/-.6), gender (45% women), interval between death and brain harvest (3.1+/-2.4h), and brain weight (1200+/-119 g) did not differ between e4 carriers (n=42) and NC. Total plaque density was higher in e4 carriers than NC (6.8+/-4.9 vs. 4.3+/-4.4, p=.002), and this was true in each of 5 subregions examined. Total CAA (p=.002) and all subregion CAA burden was also higher in e4 carriers. Total neuritic plaque density (1.2+/-1.0 vs. 1.0+/-1.0, p=.18) and total NFT density (3.9+/-2.4 vs. 3.6+/-2.3, p=.50) did not differ between e4 carriers and NC, nor in any subregion. Eliminating the 21 with MCI did not alter these results. Nondemented APOE e4 carriers over age 60 have a higher burden of total parenchymal and vascular amyloid neuropathology than NC, but no difference in neuritic plaque and NFT pathology. Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20153809      PMCID: PMC2851172          DOI: 10.1016/j.neulet.2010.02.016

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  30 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  "Preclinical" AD revisited: neuropathology of cognitively normal older adults.

Authors:  F A Schmitt; D G Davis; D R Wekstein; C D Smith; J W Ashford; W R Markesbery
Journal:  Neurology       Date:  2000-08-08       Impact factor: 9.910

3.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.

Authors:  S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

4.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.

Authors:  J E Hixson; D T Vernier
Journal:  J Lipid Res       Date:  1990-03       Impact factor: 5.922

5.  Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease.

Authors:  E M Reiman; R J Caselli; K Chen; G E Alexander; D Bandy; J Frost
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

6.  Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease.

Authors:  P V Arriagada; J H Growdon; E T Hedley-Whyte; B T Hyman
Journal:  Neurology       Date:  1992-03       Impact factor: 9.910

7.  Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles.

Authors:  David A Bennett; Philip L De Jager; Sue E Leurgans; Julie A Schneider
Journal:  Neurology       Date:  2009-04-28       Impact factor: 9.910

8.  The importance of neuritic plaques and tangles to the development and evolution of AD.

Authors:  P Tiraboschi; L A Hansen; L J Thal; J Corey-Bloom
Journal:  Neurology       Date:  2004-06-08       Impact factor: 9.910

9.  Identification of normal and pathological aging in prospectively studied nondemented elderly humans.

Authors:  D W Dickson; H A Crystal; L A Mattiace; D M Masur; A D Blau; P Davies; S H Yen; M K Aronson
Journal:  Neurobiol Aging       Date:  1992 Jan-Feb       Impact factor: 4.673

10.  Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age.

Authors:  Eloise Kok; Satu Haikonen; Teemu Luoto; Heini Huhtala; Sirkka Goebeler; Hannu Haapasalo; Pekka J Karhunen
Journal:  Ann Neurol       Date:  2009-06       Impact factor: 10.422

View more
  47 in total

Review 1.  Mild cognitive impairment: pathology and mechanisms.

Authors:  Elliott J Mufson; Lester Binder; Scott E Counts; Steven T DeKosky; Leyla de Toledo-Morrell; Stephen D Ginsberg; Milos D Ikonomovic; Sylvia E Perez; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-11-19       Impact factor: 17.088

2.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.

Authors:  Bradley T Hyman; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Maria C Carrillo; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; Bill Thies; John Q Trojanowski; Harry V Vinters; Thomas J Montine
Journal:  Alzheimers Dement       Date:  2012-01       Impact factor: 21.566

Review 3.  Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins.

Authors:  Tien-Phat V Huynh; Albert A Davis; Jason D Ulrich; David M Holtzman
Journal:  J Lipid Res       Date:  2017-02-27       Impact factor: 5.922

Review 4.  Alzheimer Disease: Scientific Breakthroughs and Translational Challenges.

Authors:  Richard J Caselli; Thomas G Beach; David S Knopman; Neill R Graff-Radford
Journal:  Mayo Clin Proc       Date:  2017-06       Impact factor: 7.616

5.  Digital pathology and image analysis for robust high-throughput quantitative assessment of Alzheimer disease neuropathologic changes.

Authors:  Janna Hackett Neltner; Erin Lynn Abner; Frederick A Schmitt; Stephanie Kay Denison; Sonya Anderson; Ela Patel; Peter T Nelson
Journal:  J Neuropathol Exp Neurol       Date:  2012-12       Impact factor: 3.685

6.  The neuropsychology of normal aging and preclinical Alzheimer's disease.

Authors:  Richard J Caselli; Dona E C Locke; Amylou C Dueck; David S Knopman; Bryan K Woodruff; Charlene Hoffman-Snyder; Rosa Rademakers; Adam S Fleisher; Eric M Reiman
Journal:  Alzheimers Dement       Date:  2013-03-26       Impact factor: 21.566

7.  Genetic influence of apolipoprotein E4 genotype on hippocampal morphometry: An N = 725 surface-based Alzheimer's disease neuroimaging initiative study.

Authors:  Jie Shi; Natasha Leporé; Boris A Gutman; Paul M Thompson; Leslie C Baxter; Richard J Caselli; Yalin Wang
Journal:  Hum Brain Mapp       Date:  2014-01-22       Impact factor: 5.038

8.  APOEε2 is associated with milder clinical and pathological Alzheimer disease.

Authors:  Alberto Serrano-Pozo; Jing Qian; Sarah E Monsell; Rebecca A Betensky; Bradley T Hyman
Journal:  Ann Neurol       Date:  2015-06       Impact factor: 10.422

9.  BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains.

Authors:  Boris Decourt; Amanda Gonzales; Thomas G Beach; Michael Malek-Ahmadi; Aaron Walker; Lucia Sue; Douglas G Walker; Marwan N Sabbagh
Journal:  Curr Alzheimer Res       Date:  2013-03       Impact factor: 3.498

10.  Surface fluid registration of conformal representation: application to detect disease burden and genetic influence on hippocampus.

Authors:  Jie Shi; Paul M Thompson; Boris Gutman; Yalin Wang
Journal:  Neuroimage       Date:  2013-04-13       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.